Alpha 2.0
Login Register
» Articles » PMID: 2939795

Ciprofloxacin Therapy of Infections Caused by Pseudomonas Aeruginosa and Other Resistant Bacteria

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 1985 Aug 1
PMID 2939795
Citations 23
Authors
L J Eron
L Harvey
D L Hixon
D M Poretz
Affiliations
Soon will be listed here.
Abstract

Ciprofloxacin was administered orally to 48 patients with 24 Pseudomonas aeruginosa infections and 13 other infections caused by cephalothin-resistant gram-negative bacilli. The types of infections treated included those of skin or skin structure, bone, urinary tract, and respiratory tract. In 83% of P. aeruginosa infections, a favorable clinical outcome occurred, compared with 85% for all infections. Failure to achieve a cure correlated with the emergence of resistant P. aeruginosa and Acinetobacter calcoaceticus strains in four instances and superinfection with Candida (two cases) and Streptococcus (two cases) species. Therapy was discontinued in three patients because of the development of nausea. Ciprofloxacin appears to be safe and effective in the therapy of infections caused by resistant gram-negative bacilli.

Citing Articles

Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model.

Ong H, Traini D, Bebawy M, Young P Antimicrob Agents Chemother. 2013; 57(6):2535-40.

PMID: 23507281 PMC: 3716180. DOI: 10.1128/AAC.00306-13.

Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection.

Marchbanks C, McKiel J, GILBERT D, Robillard N, Painter B, Zinner S Antimicrob Agents Chemother. 1993; 37(9):1756-63.

PMID: 8239581 PMC: 188066. DOI: 10.1128/AAC.37.9.1756.

nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa.

Fukuda H, Hosaka M, Iyobe S, Gotoh N, Nishino T, Hirai K Antimicrob Agents Chemother. 1995; 39(3):790-2.

PMID: 7793896 PMC: 162629. DOI: 10.1128/AAC.39.3.790.

Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa.

Xiong Y, Potel G, Caillon J, Stephant G, Jehl F, Bugnon D Antimicrob Agents Chemother. 1995; 39(2):496-9.

PMID: 7726520 PMC: 162566. DOI: 10.1128/AAC.39.2.496.

Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin.

Van der Auwera P, Klastersky J Antimicrob Agents Chemother. 1986; 30(6):892-5.

PMID: 3813515 PMC: 180614. DOI: 10.1128/AAC.30.6.892.

References
1.
Bendush C, Weber R . Tobramycin sulfate: a summary of worldwide experience from clinical trials. J Infect Dis. 1976; 134 Suppl:S219-34. DOI: 10.1093/infdis/134.supplement_1.s219. View
2.
Simon G, Snydman D, Tally F, Gorbach S . Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinical relapse. Antimicrob Agents Chemother. 1980; 18(1):167-70. PMC: 283958. DOI: 10.1128/AAC.18.1.167. View
3.
Platt R, EHRLICH S, Afarian J, OBrien T, Pennington J, KASS E . Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy. Antimicrob Agents Chemother. 1981; 20(3):351-5. PMC: 181699. DOI: 10.1128/AAC.20.3.351. View
4.
Murphy T, Barza M . Clinical experience with Moxalactam in the treatment of pseudomonal and nonpseudomonal infections. Antimicrob Agents Chemother. 1982; 21(4):568-74. PMC: 181943. DOI: 10.1128/AAC.21.4.568. View
5.
Calandra G, Hesney M, Grad C . A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam. Eur J Clin Microbiol. 1984; 3(5):478-87. DOI: 10.1007/BF02017380. View